-
Website Disclaimer
Content marked as original on the “Infectious Disease Frontier” platform holds copyright under Infectious Disease Frontier. While we encourage sharing and reproduction of our content, it must be done with prior written consent from Infectious Disease Frontier. Unauthorized use is strictly prohibited, and legal action may be taken against infringement.
-
The Role of Fanconi Anemia Signaling Pathway Genes in Myelodysplastic Syndromes and Acute Myeloid Leukemia: Insights from Mutation Spectrum, Expression Profiling, and Prognosis Evaluation
In November 2023, a study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——BMC Med Genomics. The title of the study is “Mutation spectrum, expression profiling, and prognosis evaluation of Fanconi anemia signaling pathway…
-
Pediatric Acute Myeloid Leukemia and Hyperleukocytosis: Prognostic Impact of High White Blood Cell Counts
In November 2023, a study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——Current Opinion In Pediatrics. The title of the study is “Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy”. The study represents…
-
Iron Chelation Therapy in Myelodysplastic Syndrome Mice: A Study on Erythropoiesis and Iron Overload
In December 2023, a study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal——Elife. The title of the study is “Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice”. The study provides…
-
Academician Xiaojun Huang: Conquering Leukemia with the Beijing Protocol
Huang Xiaojun, an expert in hematologic diseases, serves as the director of the Hematology Department at Peking University People’s Hospital and the head of the Hematology Disease Research Institute at…
-
Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa in Patients with Hematological Diseases
In May 2023, a study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal ——Frontiers in Cellular and Infection Microbiology. The title of the study is “Assessment of mortality-related risk factors and effective antimicrobial regimens…
-
Combatting Carbapenem-Resistant Enterobacteriaceae Bloodstream Infections in Neutropenic Pediatric Hematology Patients: A Comprehensive Analysis
In July 2023, a study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal——Antimicrobial Resistance and Infection Control. The title of the study is “High risk of bloodstream infection of carbapenem-resistant enterobacteriaceae carriers in neutropenic…
-
Measurable Residual Disease in Leukemia: Improving Qualification through MRDworst case
In November 2023, a study led by Professor XiaoFan Zhu from Chinese Academy of Medical Sciences Blood Disease Hospital (Institute of Hematology, Chinese Academy of Medical Sciences) was published in the international academic journal——Leukemia（11.4）. The title of the study is “Have we been qualifying measurable residual disease correctly?”. The comparative analysis between MRDworst case and…
Connecting Medical Expertise through Media